CSL 111

Drug Profile

CSL 111

Alternative Names: CSL-111; CSL111 (reconstituted HDL) - CSL

Latest Information Update: 08 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL
  • Class Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Stroke

Most Recent Events

  • 26 Mar 2007 Results from a phase II clinical trial (ERASE) in patients with Acute Coronary Syndrome added to the adverse events and Ischaemic Heart Disease therapeutic trials sections ,
  • 22 Nov 2006 Preclinical trials in Acute coronary syndromes in Europe (unspecified route)
  • 14 Nov 2006 Preclinical trials in Acute coronary syndromes in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top